[1]
J. A. Barkin, T. Keihanian, J. S. Barkin, C. M. Antequera, y B. Moshiree, «Preferential usage of rifaximin for the treatment of hydrogen-positive small intestinal bacterial overgrowth», Rev Gastroenterol Peru, vol. 39, n.º 2, pp. 111–5, jul. 2019.